Nifty
Sensex
:
:
13967.50
47409.93
-271.40 (-1.91%)
-937.66 (-1.94%)

Pharmaceuticals & Drugs - Global

Rating :
66/99  (View)

BSE: 524742 | NSE: CAPLIPOINT

465.85
-7.70 (-1.63%)
27-Jan-2021 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  472.95
  •  472.95
  •  463.00
  •  473.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  107198
  •  499.38
  •  686.00
  •  176.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,527.60
  • 16.10
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,336.87
  • 0.54%
  • 3.34

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.03%
  • 1.20%
  • 22.40%
  • FII
  • DII
  • Others
  • 1.64%
  • 0.60%
  • 5.13%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 29.31
  • 16.94

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 32.37
  • 5.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 36.26
  • 14.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.62
  • 22.39
  • 17.83

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.82
  • 10.05
  • 6.11

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.32
  • 17.72
  • 12.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
268.12
227.20
18.01%
240.08
192.55
24.68%
215.23
187.34
14.89%
228.21
159.03
43.50%
Expenses
180.69
156.09
15.76%
168.48
125.17
34.60%
161.43
122.58
31.69%
160.45
101.27
58.44%
EBITDA
87.43
71.11
22.95%
71.60
67.38
6.26%
53.80
64.76
-16.92%
67.77
57.76
17.33%
EBIDTM
32.61%
31.30%
29.82%
34.99%
14.01%
34.57%
29.69%
36.32%
Other Income
1.76
6.89
-74.46%
6.49
4.47
45.19%
19.63
2.67
635.21%
10.34
7.74
33.59%
Interest
0.48
0.08
500.00%
0.51
0.01
5,000.00%
0.17
0.01
1,600.00%
0.06
0.02
200.00%
Depreciation
8.88
7.40
20.00%
8.96
7.39
21.24%
8.40
6.72
25.00%
8.43
5.67
48.68%
PBT
79.83
70.52
13.20%
68.62
64.45
6.47%
64.86
60.69
6.87%
69.62
59.81
16.40%
Tax
17.00
13.25
28.30%
14.07
14.39
-2.22%
16.01
10.84
47.69%
10.73
14.00
-23.36%
PAT
62.83
57.27
9.71%
54.55
50.06
8.97%
48.86
49.86
-2.01%
58.88
45.81
28.53%
PATM
23.43%
25.21%
22.72%
26.00%
7.11%
26.61%
25.80%
28.80%
EPS
7.52
7.58
-0.79%
7.21
6.64
8.58%
28.29
6.59
329.29%
7.74
6.06
27.72%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Net Sales
951.64
863.20
648.69
539.84
401.65
238.72
251.77
173.09
127.03
107.22
80.78
Net Sales Growth
24.22%
33.07%
20.16%
34.41%
68.25%
-5.18%
45.46%
36.26%
18.48%
32.73%
 
Cost Of Goods Sold
4,980.37
413.16
288.78
238.18
184.93
121.16
135.62
102.58
84.45
77.36
60.88
Gross Profit
-4,028.73
450.04
359.91
301.66
216.72
117.56
116.15
70.50
42.58
29.85
19.89
GP Margin
-423.35%
52.14%
55.48%
55.88%
53.96%
49.25%
46.13%
40.73%
33.52%
27.84%
24.62%
Total Expenditure
671.05
602.27
416.84
344.52
276.84
174.51
192.06
136.90
104.68
96.06
71.58
Power & Fuel Cost
-
14.81
13.76
10.98
9.91
7.56
8.61
3.07
1.12
0.84
0.68
% Of Sales
-
1.72%
2.12%
2.03%
2.47%
3.17%
3.42%
1.77%
0.88%
0.78%
0.84%
Employee Cost
-
67.15
45.58
37.61
29.71
17.92
18.24
12.63
7.69
6.28
4.14
% Of Sales
-
7.78%
7.03%
6.97%
7.40%
7.51%
7.24%
7.30%
6.05%
5.86%
5.13%
Manufacturing Exp.
-
68.23
43.49
37.11
28.56
14.33
16.04
7.42
3.07
1.63
1.54
% Of Sales
-
7.90%
6.70%
6.87%
7.11%
6.00%
6.37%
4.29%
2.42%
1.52%
1.91%
General & Admin Exp.
-
25.50
20.82
12.27
13.78
8.15
7.97
6.54
4.67
3.58
3.00
% Of Sales
-
2.95%
3.21%
2.27%
3.43%
3.41%
3.17%
3.78%
3.68%
3.34%
3.71%
Selling & Distn. Exp.
-
9.95
2.08
5.92
9.41
2.29
2.85
1.46
1.02
0.91
0.67
% Of Sales
-
1.15%
0.32%
1.10%
2.34%
0.96%
1.13%
0.84%
0.80%
0.85%
0.83%
Miscellaneous Exp.
-
3.47
2.33
2.45
0.55
3.10
2.72
3.19
2.66
5.44
0.67
% Of Sales
-
0.40%
0.36%
0.45%
0.14%
1.30%
1.08%
1.84%
2.09%
5.07%
0.82%
EBITDA
280.60
260.93
231.85
195.32
124.81
64.21
59.71
36.19
22.35
11.16
9.20
EBITDA Margin
29.49%
30.23%
35.74%
36.18%
31.07%
26.90%
23.72%
20.91%
17.59%
10.41%
11.39%
Other Income
38.22
41.33
19.03
12.67
9.96
3.66
3.03
3.72
2.10
2.51
2.55
Interest
1.22
1.18
0.58
0.61
0.52
0.34
0.97
0.68
0.77
1.26
1.20
Depreciation
34.67
31.62
23.43
19.00
13.30
7.48
8.38
3.54
1.54
1.24
2.32
PBT
282.93
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
11.17
8.22
Tax
57.81
54.38
50.32
43.74
25.44
14.28
12.26
9.76
8.12
3.14
1.91
Tax Rate
20.43%
20.18%
22.18%
23.22%
21.03%
23.78%
22.96%
27.35%
36.68%
28.11%
23.24%
PAT
225.12
215.00
176.56
144.78
95.61
45.77
41.04
25.85
13.98
8.01
6.28
PAT before Minority Interest
218.84
215.08
176.56
144.63
95.50
45.77
41.13
25.93
14.02
8.03
6.31
Minority Interest
-6.28
-0.08
0.00
0.15
0.11
0.00
-0.09
-0.08
-0.04
-0.02
-0.03
PAT Margin
23.66%
24.91%
27.22%
26.82%
23.80%
19.17%
16.30%
14.93%
11.01%
7.47%
7.77%
PAT Growth
10.90%
21.77%
21.95%
51.43%
108.89%
11.53%
58.76%
84.91%
74.53%
27.55%
 
Unadjusted EPS
29.78
28.44
23.35
19.15
12.65
6.05
5.43
3.42
1.85
1.06
0.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Shareholder's Funds
947.91
632.91
363.83
224.76
128.14
93.19
61.74
43.14
33.58
29.08
Share Capital
89.71
51.05
15.12
15.12
15.11
15.11
15.11
15.11
15.11
15.11
Total Reserves
848.76
575.01
345.42
209.56
111.40
78.08
46.63
28.03
18.47
13.97
Non-Current Liabilities
24.86
23.42
27.86
19.90
13.69
10.39
10.42
8.66
4.29
1.82
Secured Loans
0.02
0.29
0.32
0.48
0.73
0.88
2.07
3.48
1.55
0.08
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
5.23
0.13
0.00
0.40
1.63
0.82
0.81
0.38
0.27
0.20
Current Liabilities
144.32
86.11
108.67
113.36
125.04
124.97
107.58
83.01
69.20
40.44
Trade Payables
64.14
60.47
94.23
78.60
55.71
41.56
31.50
25.64
21.26
17.06
Other Current Liabilities
79.28
24.20
13.86
33.09
60.39
72.11
66.42
50.85
38.33
10.71
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.05
0.05
0.05
5.20
9.46
Short Term Provisions
0.91
1.44
0.58
1.67
8.94
11.25
9.60
6.47
4.41
3.22
Total Liabilities
1,125.75
742.52
500.45
358.38
267.14
228.82
179.92
134.90
107.12
71.37
Net Block
272.50
226.84
169.48
151.83
144.23
113.13
102.24
32.71
27.54
24.95
Gross Block
354.79
271.51
231.79
195.15
180.76
142.71
123.06
50.06
43.36
39.53
Accumulated Depreciation
82.29
44.67
62.31
43.31
36.53
29.58
20.82
17.36
15.82
14.58
Non Current Assets
303.23
248.83
196.34
179.16
148.61
146.95
131.30
96.21
53.41
30.12
Capital Work in Progress
20.12
9.70
15.29
3.42
0.23
30.63
24.54
48.98
12.79
0.17
Non Current Investment
0.56
0.33
0.33
13.24
0.44
0.45
0.44
1.19
1.14
1.15
Long Term Loans & Adv.
10.05
11.95
11.23
10.67
3.71
2.75
3.67
10.83
11.94
3.85
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
822.53
493.69
304.11
179.22
118.53
81.87
48.61
38.70
53.71
41.25
Current Investments
60.23
69.62
46.34
4.20
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
238.23
37.45
28.46
22.29
18.81
13.66
9.79
10.42
6.38
5.50
Sundry Debtors
228.96
159.81
125.88
33.02
7.95
5.66
0.09
0.86
7.28
8.33
Cash & Bank
223.43
152.99
79.28
93.07
68.10
45.37
26.82
16.84
31.80
21.62
Other Current Assets
71.68
9.22
6.88
7.32
23.67
17.18
11.90
10.57
8.25
5.80
Short Term Loans & Adv.
56.81
64.61
17.28
19.31
12.58
11.08
8.16
5.61
4.50
3.44
Net Current Assets
678.21
407.58
195.44
65.86
-6.51
-43.10
-58.97
-44.31
-15.49
0.81
Total Assets
1,125.76
742.52
500.45
358.38
267.14
228.82
179.91
134.91
107.12
71.37

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Cash From Operating Activity
44.68
83.42
66.49
67.61
42.40
49.88
59.83
31.95
27.92
14.25
PBT
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
11.17
8.22
Adjustment
7.09
19.12
14.84
8.61
3.87
6.21
2.14
-0.21
-0.25
2.06
Changes in Working Capital
-177.11
-120.06
-100.38
-38.39
-5.13
1.96
29.32
15.81
18.89
4.49
Cash after chg. in Working capital
99.44
125.94
102.84
91.16
58.78
61.56
67.15
37.75
29.81
14.77
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-54.76
-42.51
-36.35
-23.55
-16.38
-11.67
-7.32
-5.80
-1.89
-0.52
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-54.50
-100.46
-69.02
-36.11
-5.72
-22.66
-43.89
-45.44
-16.44
-6.90
Net Fixed Assets
-43.65
58.45
-48.43
-19.56
-7.66
-25.72
-48.50
-43.00
-16.08
Net Investments
-27.53
-120.03
-29.43
-17.35
0.01
-0.90
0.75
-0.05
-0.04
Others
16.68
-38.88
8.84
0.80
1.93
3.96
3.86
-2.39
-0.32
Cash from Financing Activity
79.77
89.79
-11.60
-6.74
-13.95
-8.67
-5.96
-1.48
-1.30
-0.37
Net Cash Inflow / Outflow
69.94
72.76
-14.13
24.76
22.73
18.55
9.99
-14.97
10.18
6.98
Opening Cash & Equivalents
150.65
77.17
91.31
66.55
45.37
26.82
16.84
31.80
21.62
14.64
Closing Cash & Equivalent
220.77
150.65
77.17
91.31
68.10
45.37
26.82
16.84
31.80
21.62

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Book Value (Rs.)
114.21
78.03
47.69
29.73
16.25
11.84
7.68
5.22
3.95
3.36
ROA
23.02%
28.41%
33.68%
30.54%
18.46%
20.12%
16.48%
11.59%
9.00%
8.84%
ROE
29.58%
37.14%
49.43%
54.97%
43.13%
55.78%
53.24%
40.49%
29.10%
24.90%
ROCE
33.46%
45.59%
64.08%
69.03%
55.41%
71.11%
68.99%
56.69%
34.62%
26.87%
Fixed Asset Turnover
2.76
2.58
2.53
2.14
1.48
1.89
2.00
2.73
2.61
2.04
Receivable days
82.19
80.37
53.72
18.62
10.40
4.17
1.00
11.66
26.30
37.63
Inventory Days
58.28
18.54
17.16
18.68
24.83
17.00
21.31
24.06
20.01
24.84
Payable days
28.33
65.76
89.68
88.17
103.48
69.75
79.69
85.60
79.07
88.42
Cash Conversion Cycle
112.15
33.15
-18.80
-50.88
-68.24
-48.58
-57.39
-49.89
-32.75
-25.95
Total Debt/Equity
0.04
0.00
0.00
0.00
0.02
0.02
0.06
0.12
0.23
0.38
Interest Cover
228.51
391.22
309.72
235.08
179.35
56.11
53.29
29.73
9.88
7.84

Annual Reports:


News Update


  • Caplin Point Laboratories’ arm gets USFDA approval for Argatroban Injection
    22nd Jan 2021, 12:30 PM

    Argatroban is used as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia

    Read More
  • Caplin Point Laboratories’ arm enters into strategic partnership with JAMP Pharma Group
    18th Jan 2021, 11:11 AM

    The company has entered into a strategic partnership with JAMP Pharma Group for six injectable products

    Read More
  • Caplin Point Laboratories’ arm gets approval for Etomidate injection
    24th Dec 2020, 15:34 PM

    Etomidate injection USP had US sales data of approximately $9 million for the 12-month period ending October 2020

    Read More
  • Caplin Point Lab - Quarterly Results
    5th Nov 2020, 12:20 PM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.